-
American Journal of Men's Health 2022We performed a systematic review and meta-analysis on efficacy and safety of holmium laser enucleation of prostate compared with bipolar technologies in treating benign... (Meta-Analysis)
Meta-Analysis Review
The Efficacy and Safety of Holmium Laser Enucleation of Prostate Compared With Bipolar Technologies in Treating Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials.
We performed a systematic review and meta-analysis on efficacy and safety of holmium laser enucleation of prostate compared with bipolar technologies in treating benign prostatic hyperplasia. We analyzed several databases such PubMed, Embase, and Web of Science. Two reviewers independently reviewed studies for consistent criteria and extracted relevant data. Reviewers independently assessed the risk of bias and strength of the evidence for the body of the literature. Ten randomized controlled trials including 1,157 participants were included in this meta-analysis. The holmium laser group had favorable perioperative outcomes in this study. The holmium laser group identified shorter catheterization duration and shorter hospital stay duration than the bipolar technologies group. Efficiency outcomes, such as International Prostate Symptom Score, peak urinary flow rate, quality of life, postvoid residual urine volume, and international index of erectile function reported no obvious differences between the holmium laser and bipolar technologies groups at the 6 to 12 months follow-up. Bipolar technologies and holmium laser groups shared equivalent effectiveness and safety in treatments for benign prostate hyperplasia. Holmium lasers identified lower catheter times, shorter hospital stays, and lesser risk of hemorrhage than bipolar technologies.
Topics: Humans; Male; Prostatic Hyperplasia; Lasers, Solid-State; Prostate; Quality of Life; Randomized Controlled Trials as Topic
PubMed: 36484312
DOI: 10.1177/15579883221140211 -
Redox Biology Sep 2023Mitoquinone (MitoQ), a mitochondria-targeted antioxidant, has been used to treat several diseases. The present study aimed to investigate the therapeutic effects of...
Mitoquinone (MitoQ), a mitochondria-targeted antioxidant, has been used to treat several diseases. The present study aimed to investigate the therapeutic effects of MitoQ in benign prostatic hyperplasia (BPH) models and their underlying molecular mechanisms. In this study, we determined that MitoQ inhibited dihydrotestosterone (DHT)-induced cell proliferation and mitochondrial ROS by inhibiting androgen receptor (AR) and NOD-like receptor family pyrin domain-containing 3 (NLRP3) signaling in prostate epithelial cells. Molecular modeling revealed that DHT may combine with AR and NLRP3, and that MitoQ inhibits both AR and NLRP3. AR and NLRP3 downregulation using siRNA showed the linkage among AR, NLRP3, and MitoQ. MitoQ administration alleviated pathological prostate enlargement and exerted anti-proliferative and antioxidant effects by suppressing the AR and NLRP3 signaling pathways in rats with BPH. Hence, our findings demonstrated that MitoQ is an inhibitor of NLPR3 and AR and a therapeutic agent for BPH treatment.
Topics: Male; Humans; Rats; Animals; Prostatic Hyperplasia; Antioxidants; Receptors, Androgen; NLR Family, Pyrin Domain-Containing 3 Protein
PubMed: 37454529
DOI: 10.1016/j.redox.2023.102816 -
Biomedicine & Pharmacotherapy =... Nov 2023One of the most common urological diseases is benign prostatic hyperplasia (BPH), with a high prevalence in the middle-aged and elderly male population. Patient's mental... (Review)
Review
One of the most common urological diseases is benign prostatic hyperplasia (BPH), with a high prevalence in the middle-aged and elderly male population. Patient's mental and physical health is affected significantly by this condition, causing them considerable discomfort. During the development of BPH, a synergistic effect occurs in response to inflammation, oxidative stress, and apoptosis induced by the activation of macrophages. The nuclear factor erythroid2-related factor 2 (Nrf2) signaling pathway can mediate macrophage activation and inhibit prostate hyperplasia by suppressing pro-inflammatory factors, anti-oxidative stress disorder, and initiating apoptosis. The purpose of this study was to review the mechanism of action of Nrf2 signaling pathway-mediated macrophage activation on the immune microenvironment of BPH and to summarize the Chinese medicine based on Nrf2 to provide an overview of BPH treatment options.
Topics: Aged; Humans; Male; Middle Aged; Inflammation; Macrophages; NF-E2-Related Factor 2; Prostatic Hyperplasia; Signal Transduction
PubMed: 37778273
DOI: 10.1016/j.biopha.2023.115566 -
The American Journal of Pathology Feb 2015The prostate is an androgen-sensitive organ that needs proper androgen/androgen receptor (AR) signals for normal development. The progression of prostate diseases,... (Review)
Review
The prostate is an androgen-sensitive organ that needs proper androgen/androgen receptor (AR) signals for normal development. The progression of prostate diseases, including benign prostate hyperplasia (BPH) and prostate cancer (PCa), also needs proper androgen/AR signals. Tissue recombination studies report that stromal, but not epithelial, AR plays more critical roles via the mesenchymal-epithelial interactions to influence the early process of prostate development. However, in BPH and PCa, much more attention has been focused on epithelial AR roles. However, accumulating evidence indicates that stromal AR is also irreplaceable and plays critical roles in prostate disease progression. Herein, we summarize the roles of stromal AR in the development of normal prostate, BPH, and PCa, with evidence from the recent results of in vitro cell line studies, tissue recombination experiments, and AR knockout animal models. Current evidence suggests that stromal AR may play positive roles to promote BPH and PCa progression, and targeting stromal AR selectively with AR degradation enhancer, ASC-J9, may allow development of better therapies with fewer adverse effects to battle BPH and PCa.
Topics: Animals; Curcumin; Humans; Male; Neoplasm Proteins; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction
PubMed: 25432062
DOI: 10.1016/j.ajpath.2014.10.012 -
Cirugia Y Cirujanos 2023Lower urinary tract symptoms due to benign prostatic hyperplasia in men increase with aging. Risks related to anesthesia and surgery have led a search for alternative...
OBJECTIVES
Lower urinary tract symptoms due to benign prostatic hyperplasia in men increase with aging. Risks related to anesthesia and surgery have led a search for alternative treatments. Bipolar radiofrequency (RF) thermotherapy is one of the methods adopted in patients with high surgical risks. The aim of this study is to compare the effect of bipolar RF thermotherapy and transurethral resection of the prostate (TURP) methods on voiding symptoms and on post-operative complication rates especially in patients carrying high surgical risks.
METHODS
Pre-operative, post-operative 1 and 6 month International Prostate Symptom Score (IPSS), Qmax, quality of life, prostate volumes, and postoperative complications of the patients underwent TURP and RF for benign prostatic hyperplasia (BPH) were compared.
RESULTS
In the RF group, the pre-operative median IPSS was 30, prostate volume 41.5 cc, post-void residual (PVR) 80 ml, and Qmax is 5.85 ml/s.; In the TURP group, these were 29, 40 cc, 85 ml, and 5.3 ml/sec, respectively. In the Bipolar RF group, post-operative 1- and 6-month median values were IPSS 18, 21; prostate volume 40, 40; PVR 40, 35; Qmax 10.9, 9.15 and in the TURP group IPSS 9, 8; prostate volume 20, 20; PVR 30, 10; Qmax 17.25, 19.1, respectively.
CONCLUSION
Bipolar RF thermotherapy is an applicable treatment method for BPH patients with high surgical risks.
Topics: Male; Humans; Transurethral Resection of Prostate; Prostate; Prostatic Hyperplasia; Quality of Life; Hyperplasia; Treatment Outcome; Postoperative Complications; Hyperthermia, Induced
PubMed: 38096863
DOI: 10.24875/CIRU.23000020 -
Australian Journal of General Practice Jul 2018Benign prostatic hyperplasia (BPH) is the most common benign tumour in men. Although men with BPH often need medical or surgical management from a urologist at some... (Review)
Review
BACKGROUND
Benign prostatic hyperplasia (BPH) is the most common benign tumour in men. Although men with BPH often need medical or surgical management from a urologist at some point throughout the timeline of their disease, most men are initially assessed and managed by a general practitioner (GP) in the primary healthcare setting.
OBJECTIVE
The aim of this article is to highlight the principles of the pathogenesis, presentation, assessment and management of BPH in a primary care setting.
DISCUSSION
Between 2009 and 2011, BPH was managed by GPs at approximately 228,000 general practice visits per annum in Australia. Several changes in pharmaceutical agents and surgical intervention have occurred over the past decade. As a result, it is imperative that GPs remain up to date with assessment and management of BPH, are aware of new therapies and understand when to refer to a urologist.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Australia; General Practice; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostate; Prostatectomy; Prostatic Hyperplasia
PubMed: 30114865
DOI: 10.31128/AFP-08-17-4292 -
BioMed Research International 2013Benign Prostate hyperplasia (BPH) and prostate cancer (PCa) are the most common prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance,... (Review)
Review
Benign Prostate hyperplasia (BPH) and prostate cancer (PCa) are the most common prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance, disruption of cell proliferation, apoptosis, chronic inflammation, and aging are thought to be responsible for the pathophysiology of these diseases. Both BPH and PCa are considered to be arisen from aberrant proliferation of prostate stem cells. Recent studies on BPH and PCa have provided significant evidence for the origin of these diseases from stem cells that share characteristics with normal prostate stem cells. Aberrant changes in prostate stem cell regulatory factors may contribute to the development of BPH or PCa. Understanding these regulatory factors may provide insight into the mechanisms that convert quiescent adult prostate cells into proliferating compartments and lead to BPH or carcinoma. Ultimately, the knowledge of the unique prostate stem or stem-like cells in the pathogenesis and development of hyperplasia will facilitate the development of new therapeutic targets for BPH and PCa. In this review, we address recent progress towards understanding the putative role and complexities of stem cells in the development of BPH and PCa.
Topics: Animals; Apoptosis; Humans; Inflammation; Male; Neoplastic Stem Cells; Prostatic Hyperplasia; Prostatic Neoplasms
PubMed: 23936768
DOI: 10.1155/2013/107954 -
Scientific Reports Aug 2023The study aimed to assess the biocompatibility and efficacy of a prostatic urethral lift (PUL) for benign prostatic hyperplasia (BPH). Human BPH-1 cells were co-cultured...
The study aimed to assess the biocompatibility and efficacy of a prostatic urethral lift (PUL) for benign prostatic hyperplasia (BPH). Human BPH-1 cells were co-cultured with implant anchors and sutures, and cytotoxicity was measured. Scanning electron microscopy (SEM) was used to observe adhesion and growth of cells and to evaluate implant biocompatibility. Fifteen male beagle dogs were randomly assigned to the surgical (n = 9) or sham-operated (n = 6) groups. The surgical group underwent cystotomy, and PUL was used to insert two implants in each lobe of the prostate to compress the enlarged prostate and dilate the urethra; the sham group underwent cystotomy without implant insertion. Compared with the control group, no significant difference in cell viability among the groups with different co-culture times of implant anchors and sutures (P > 0.05) was observed. SEM revealed good adhesion and growth of prostate cells on the implants. Improvements in urine flow rates remained stable at 7, 28, and 180 days after surgery, and the urethral diameter in the prostate region was significantly increased compared with that before surgery. PUL is a biocompatible and effective treatment for BPH, improving the urine flow rate without causing inflammation, tissue damage, or cytotoxic effects. Here, the basis for further PUL application was provided.
Topics: Animals; Dogs; Humans; Male; Canidae; Hyperplasia; Prostate; Prostatic Hyperplasia; Research Design; Urethra
PubMed: 37620451
DOI: 10.1038/s41598-023-40889-w -
The Canadian Journal of Urology Aug 2013Benign prostatic hyperplasia (BPH) is a more common form of lower urinary tract symptoms (LUTS). BPH is due to the excessive growth of both stromal and epithelial cells... (Review)
Review
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a more common form of lower urinary tract symptoms (LUTS). BPH is due to the excessive growth of both stromal and epithelial cells of the prostate. Fifty percent of men over the age of 50 will have this disease, along with the probability that 90% of men at the age of 80 will have an enlarged prostate. The prevalence of vitamin D deficiency in the male urological population may represent a connection between BPH and vitamin D.
MATERIAL AND METHODS
This review is geared to provide the most relevant data on the correlation between vitamin D and BPH. A comprehensive review was conducted on all studies on the specific topic and compiled into a complete article.
RESULTS
Data suggests that vitamin D has an inhibitory effect on the RhoA/ROCK pathway, along with cyclooxygenase-2 expression and prostaglandin E2 production in BPH stromal cells. Increasing intake of vitamin D from diet and supplements has shown a correlation with decreased BPH prevalence. Vitamin D analogues of up to 6000 IU/day have shown to decrease prostate volume in BPH patients. Pre-clinical trials have shown vitamin D to not only decrease BPH cell and prostate cell proliferation alone, but also when induced by known growth promoting molecules such as IL-8, Des (1-3) IGF-1, testosterone and dihydrotestosterone. Among all the studies there has not been any side effects or negative implications with increased vitamin D intake.
CONCLUSION
The impact of vitamin D on prostate volume and BPH has shown promising results, thus proposing further studies on vitamin D and BPH be conducted.
Topics: Cell Proliferation; Humans; Male; Organ Size; Prevalence; Prostate; Prostatic Hyperplasia; Risk Factors; Vitamin D; Vitamin D Deficiency
PubMed: 23930605
DOI: No ID Found -
The Journal of International Medical... Nov 2019To assess the potential relationship between benign prostate hyperplasia (BPH) and metabolic syndrome in men under 60 years old. (Meta-Analysis)
Meta-Analysis
OBJECTIVE
To assess the potential relationship between benign prostate hyperplasia (BPH) and metabolic syndrome in men under 60 years old.
METHODS
We searched the Medline, Embase, and Web of Science databases for studies of patients with metabolic syndrome and BPH using the key words ‘metabolic syndrome’, ‘benign prostatic hyperplasia’, and ‘BPH’. The odds ratios (ORs) and 95% confidence intervals (95%CIs) were extracted from the included studies and the role of metabolic syndrome in BPH and its characteristics (International Prostate Symptom Score (IPSS), total prostate volume (TPV), postvoid residual (PVR)) were evaluated by meta-analysis.
RESULTS
Six comparative studies comprising 61,826 individuals were identified and included in this meta-analysis. There were significant correlations between metabolic syndrome and BPH (OR = 1.24, 95%CI = 1.19–1.29), clinical BPH (OR = 1.37, 95%CI = 1.03–1.70), and TPV (OR = 2.34, 95%CI = 1.25–3.42). However, there was no significant association between metabolic syndrome and IPSS (OR = 1.19, 95%CI = 0.35–2.04) or PVR (OR = 2.15, 95% CI = 0.95–3.34).
CONCLUSIONS
These results indicate that metabolic syndrome is significantly and positively correlated with the incidence of BPH in younger men aged <60 years. However, there was no significant relationship between metabolic syndrome and BPH-related symptoms.
Topics: Humans; Male; Metabolic Syndrome; Middle Aged; Prostatic Hyperplasia
PubMed: 31612766
DOI: 10.1177/0300060519876823